BIOPHARMX CORPORATION (NASDAQ:BPMX) Files An 8-K Entry into a Material Definitive Agreement

BIOPHARMX CORPORATION (NASDAQ:BPMX) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01.  Entry into a Material Definitive Agreement

Story continues below

On December 14, 2016, BioPharmX, Inc., a Nevada corporation and wholly-owned subsidiary of BioPharmX Corporation (“Company”), and Refuge Biotechnologies, Inc., a Delaware corporation, entered into a Sublease Agreement (“Sublease”) for the lease of approximately 12,066 square feet of office and laboratory space located at 1505 Adams Drive, Menlo Park, California, which will replace the Company’s current corporate headquarters.  This facility will serve as the new principal executive office and laboratory for the Company.  The term of the lease is for one year commencing on December 15, 2016.  The Company’s monthly base rent obligation is $51,280 and the Company will also be obligated to pay its proportionate share of certain expenses associated with the maintenance, repair and operation of the facility.

The foregoing description is qualified in its entirety by reference to the Sublease, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d)

Exhibit No.Description

10.1 Sublease agreement between BioPharmX, Inc. and Refuge Biotechnologies, Inc., dated December 14, 2016.

3


About BIOPHARMX CORPORATION (NASDAQ:BPMX)


An ad to help with our costs